INSM
Insmed Inc
OpenVolumeMkt capP/EEPSDiv yield
Day – 52-wk –
Expected move
InputsNext report
Last report
Largest filed tie
13F top-10 QoQ
Top fund weight
Last reportshaded = implied▲▼ = realized× = |realized| ÷ implied
Insmed has 12 disclosed suppliers and 2 disclosed customers in SEC filings.
SentenceIn September 2018, we entered into an agreement (the Lease) with Bridgewater Biotech Center LLC (assumed from Exeter 700 Route 202/206, LLC) to lease 117,022 square feet of office space located in Bridgewater, New Jersey for our corporate headquarters.
INSM 10-Kaccession 0001104506-26-000009
SentenceIn addition, Esteve manufactures the active pharmaceutical ingredient for brensocatib, and Patheon Inc. manufactures our current supply of BRINSUPRI.
INSM 10-Kaccession 0001104506-26-000009
SentenceIn December 2025, we acquired the global rights to O pSCF (renamed INS1148) from Opsidio.
INSM 10-Kaccession 0001104506-26-000009
SentenceIn July 2014, we entered into a Commercialization Agreement with PARI for the manufacture and supply of Lamira, which is an e-Flow ® nebulizer modified and optimized for use with ARIKAYCE.
INSM 10-Kaccession 0001104506-26-000009
SentenceIn January 2024, we entered into certain agreements with Patheon Inc., a wholly-owned subsidiary of Thermo Fisher, related to the manufacture and supply of commercial brensocatib products, including BRINSUPRI, for our commercial needs and brensocatib for our clinical needs by Patheon Inc.
INSM 10-Kaccession 0001104506-26-000009
SentenceIn addition, Esteve manufactures the active pharmaceutical ingredient for brensocatib, and Patheon Inc. manufactures our current supply of BRINSUPRI.
INSM 10-Kaccession 0001104506-26-000009
SentenceIn April 2020, we entered into a master services agreement with PPD Development, L.P. (PPD) pursuant to which we retained PPD to perform clinical development services in connection with certain of our clinical research programs.
INSM 10-Kaccession 0001104506-26-000009
SentenceIn connection with our purchase of INS1148, we became exclusive licensee to certain patents from the Regents of the University of Michigan (Michigan), including US Patent Nos. 9,353,178, 9,790,272 and 10,501,535.
INSM 10-Kaccession 0001104506-26-000009
SentenceIn December 2023, we entered into a license agreement with NCH, pursuant to which we were granted an exclusive license under certain patents covering INS1202, to develop and commercialize INS1202 on a worldwide basis.
INSM 10-Kaccession 0001104506-26-000009
SentenceResilience manufactures placebo for our clinical trials and our current supply of ARIKAYCE for commercial sale.
INSM 10-Kaccession 0001104506-26-000009
SentenceIn January 2023, we acquired Vertuis, a privately held, pre-clinical stage company.
INSM 10-Kaccession 0001104506-26-000009
SentenceA significant portion of our current ARIKAYCE and BRINSUPRI revenues in the US are dependent on Medicare reimbursement, and we expect that trend to continue.
INSM 10-Kaccession 0001104506-26-000009
SentenceWe are required to deliver to Patheon Inc. the active pharmaceutical ingredient needed to manufacture BRINSUPRI.
INSM 10-Kaccession 0001104506-26-000009
Insmed Inc
112.65
Linked news
NewsExpected move
Inputsspot 112.58exp Feb 19ATM strike 115ATM straddle 25.15IV 50%